PE20181162A1 - Formulaciones de pirofosfato ferrico solido soluble, kits, y metodos de uso de las mismas - Google Patents

Formulaciones de pirofosfato ferrico solido soluble, kits, y metodos de uso de las mismas

Info

Publication number
PE20181162A1
PE20181162A1 PE2018000341A PE2018000341A PE20181162A1 PE 20181162 A1 PE20181162 A1 PE 20181162A1 PE 2018000341 A PE2018000341 A PE 2018000341A PE 2018000341 A PE2018000341 A PE 2018000341A PE 20181162 A1 PE20181162 A1 PE 20181162A1
Authority
PE
Peru
Prior art keywords
soluble
ferric pyrophosphate
kits
methods
soluble ferric
Prior art date
Application number
PE2018000341A
Other languages
English (en)
Spanish (es)
Inventor
Robert Chioini
Ajay Gupta
Original Assignee
Rockwell Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rockwell Medical Inc filed Critical Rockwell Medical Inc
Publication of PE20181162A1 publication Critical patent/PE20181162A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654—Dialysates therefor
    • A61M1/1656—Apparatus for preparing dialysates
    • A61M1/1666—Apparatus for preparing dialysates by dissolving solids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)
PE2018000341A 2015-09-04 2016-09-02 Formulaciones de pirofosfato ferrico solido soluble, kits, y metodos de uso de las mismas PE20181162A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562214908P 2015-09-04 2015-09-04

Publications (1)

Publication Number Publication Date
PE20181162A1 true PE20181162A1 (es) 2018-07-19

Family

ID=56926337

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000341A PE20181162A1 (es) 2015-09-04 2016-09-02 Formulaciones de pirofosfato ferrico solido soluble, kits, y metodos de uso de las mismas

Country Status (18)

Country Link
US (1) US11517555B2 (cg-RX-API-DMAC7.html)
EP (1) EP3344235A1 (cg-RX-API-DMAC7.html)
JP (1) JP7055738B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180050346A (cg-RX-API-DMAC7.html)
CN (1) CN108601738A (cg-RX-API-DMAC7.html)
AU (1) AU2016315877B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018004244A2 (cg-RX-API-DMAC7.html)
CA (1) CA2997328A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018000566A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018002421A2 (cg-RX-API-DMAC7.html)
EA (1) EA201890642A1 (cg-RX-API-DMAC7.html)
IL (1) IL257796B (cg-RX-API-DMAC7.html)
MX (1) MX2018002633A (cg-RX-API-DMAC7.html)
PE (1) PE20181162A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018500463A1 (cg-RX-API-DMAC7.html)
SG (1) SG10202107245UA (cg-RX-API-DMAC7.html)
UA (1) UA124923C2 (cg-RX-API-DMAC7.html)
WO (1) WO2017040937A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN110063965A (zh) * 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
FR3109734B1 (fr) * 2020-05-04 2025-04-11 Univ Claude Bernard Lyon Système de dialyse pour le traitement du sepsis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177068A (en) * 1984-04-19 1993-01-05 National Research Development Corporation Pharmaceutical compositions
WO1997014407A1 (en) * 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Insoluble drug delivery
US6779468B1 (en) 1997-08-07 2004-08-24 Ajay Gupta Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients
US6689275B1 (en) 1996-12-31 2004-02-10 Ajay Gupta Method and pharmaceutical composition for replacing iron losses in dialysis patients
JP3778240B2 (ja) 1998-06-22 2006-05-24 ライオン株式会社 不快な味がマスキングされた造粒組成物及びその製造方法
CA2344548C (en) * 1998-09-18 2007-03-13 Rockwell Medical Technologies, Inc. Method and apparatus for preparing liquid dialysate
WO2001080828A2 (en) * 2000-04-20 2001-11-01 Rtp Pharma Inc. Improved water-insoluble drug particle process
CA2433169A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Porous substances and methods for producing the same
JP2002302435A (ja) * 2000-12-26 2002-10-18 Takeda Chem Ind Ltd 多孔性物質およびその製造法
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
US20060134227A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Compositions including iron
US7857977B2 (en) * 2005-07-12 2010-12-28 Rockwell Medical Technologies, Inc. Packaging of ferric pyrophosphate for dialysis
EP1743530B1 (en) * 2005-07-15 2011-08-31 Unilever N.V. Iron fortified food product and additive
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US8178709B2 (en) 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
WO2012092305A2 (en) 2010-12-27 2012-07-05 Incube Labs, Llc Nanonized iron compositions and methods of use thereof
WO2014121155A1 (en) 2013-02-01 2014-08-07 Charak Llc Methods of treating iron deficiency with soluble ferric pyrophosphate

Also Published As

Publication number Publication date
KR20180050346A (ko) 2018-05-14
JP2018529674A (ja) 2018-10-11
CA2997328A1 (en) 2017-03-09
JP7055738B2 (ja) 2022-04-18
WO2017040937A1 (en) 2017-03-09
MX2018002633A (es) 2019-02-07
CN108601738A (zh) 2018-09-28
UA124923C2 (uk) 2021-12-15
CL2018000566A1 (es) 2018-08-03
CO2018002421A2 (es) 2018-07-19
IL257796A (en) 2018-04-30
AU2016315877B2 (en) 2022-05-26
EA201890642A1 (ru) 2018-10-31
SG10202107245UA (en) 2021-08-30
US20180243256A1 (en) 2018-08-30
BR112018004244A2 (pt) 2018-09-25
IL257796B (en) 2021-09-30
AU2016315877A1 (en) 2018-04-05
US11517555B2 (en) 2022-12-06
EP3344235A1 (en) 2018-07-11
PH12018500463A1 (en) 2018-09-17

Similar Documents

Publication Publication Date Title
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CL2017003356A1 (es) Moduladores cot y métodos de uso de los mismos
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
CL2014001291A1 (es) Agentes de iarn de doble hebra; composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr).
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
CL2017003107A1 (es) Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
CR20140175A (es) Compuestos y métodos para mejorar las respuestas inmunitarias innatas
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
UY35747A (es) Derivados sustituidos de fenilalanina
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
MX2019005925A (es) Composiciones de alergenos liquidas y metodos para la preparacion de las mismas.
CL2018000566A1 (es) Formulaciones de pirofosfato férrico sólido soluble, kits, y métodos de uso de las mismas
UY34082A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona,preparación de los mismos y uso terapéutico de los mismos
UY34761A (es) Composiciones parasiticidas que comprenden derivados de benzimidazol, métodos y usos de los mismos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal